Successful response to rituximab in two cases of acquired haemophilia refractory to standard-therapy

P. Machado, J. M. Raya, T. Martín, L. Morabito, M. L. Brito, J. M. Rodríguez-Martín

Research output: Contribution to journalArticlepeer-review


Acquired autoantibodies against coagulation factors (acquired haemophilia) frequently constitute a life-threatening bleeding situation requiring a prompt therapeutic intervention, including control of bleeding and secondarily an attempt of eradication of the inhibitor by prolonged immunosuppressive therapy. The combination of oral corticosteroids and cyplophosphamide seems to be effective to eradicate the autoantibody, but some patients may be resistant. Another therapeutic approach, recently described, observes treatment with the chimeric anti-CD20 monoclonal antibody rituximab. We report two consecutively treated patients whose acquired FVIII inhibitors did not respond to standard immunosuppressive regimens, and only when rituximab was added to therapy, complete response and prolonged remission were obtained.

Original languageEnglish
Pages (from-to)545-549
Number of pages5
JournalInternational Journal of Hematology
Issue number5
Publication statusPublished - Jun 2008


  • Acquired haemophilia
  • Coagulation inhibitor
  • Factor VIII inhibitor
  • Rituximab

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Successful response to rituximab in two cases of acquired haemophilia refractory to standard-therapy'. Together they form a unique fingerprint.

Cite this